DrugPatentWatch Database Preview
VABOMERE Drug Profile
Which patents cover Vabomere, and what generic alternatives are available?
Vabomere is a drug marketed by Rempex Pharms and is included in one NDA. There are four patents protecting this drug.
This drug has twenty-nine patent family members in twenty countries.
The generic ingredient in VABOMERE is meropenem; vaborbactam. There are thirty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the meropenem; vaborbactam profile page.
Summary for VABOMERE
| International Patents: | 29 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 1 |
| Clinical Trials: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VABOMERE |
| DailyMed Link: | VABOMERE at DailyMed |
Generic Entry Opportunity Date for VABOMERE
Generic Entry Date for VABOMERE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;IV (INFUSION) |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VABOMERE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Biomedical Advanced Research and Development Authority | Phase 1 |
| Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) | Phase 1 |
Pharmacology for VABOMERE
| Drug Class | beta Lactamase Inhibitor Penem Antibacterial |
| Mechanism of Action | beta Lactamase Inhibitors |
Synonyms for VABOMERE
| 2031124-72-6 |
| Carbavance |
| Meropenem / vaborbactam |
| Meropenem and vaborbactam |
| Meropenem mixture with vaborbactam |
US Patents and Regulatory Information for VABOMERE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rempex Pharms | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Rempex Pharms | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Rempex Pharms | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Rempex Pharms | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VABOMERE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101987091 | Start Trial |
| Canada | 2807546 | Start Trial |
| Japan | 2013535502 | Start Trial |
| Mexico | 2013001517 | Start Trial |
| Japan | 2017052794 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VABOMERE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2603514 | CA 2019 00015 | Denmark | Start Trial | PRODUCT NAME: EN KOMBINATION AF VABORBACTAM, OG/ELLER ET SALT OG/ELLER HYDRAT DERAF, OG MEROPENEM, OG/ELLER ET SALT OG/ELLER HYDRAT DERAF, SAERLIGT MEROPENEM TRIHYDRAT; REG. NO/DATE: EU/1/18/1334 20181122 |
| 2603514 | 300978 | Netherlands | Start Trial | PRODUCT NAME: VABORBACTAM, EN/OF EEN ZOUT EN/OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1334 20181122 |
| 2603514 | 2019C/515 | Belgium | Start Trial | PRODUCT NAME: VABORBACTAM ET / OU D'UN DE SES SELS ET / OU HYDRATES; AUTHORISATION NUMBER AND DATE: EU/1/18/1334 20181122 |
| 2603514 | 2019C/514 | Belgium | Start Trial | PRODUCT NAME: UNE COMBINAISON DE VABORBACTAM, ET / OU D'UN DE SES SELS ET / OU HYDRATES, ET DU MEROPENEME, ET / OU DE SON SEL ET / OU DE SON HYDRATE, EN PARTICULIER DU MEROPENEME TRIHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/18/1334 20181122 |
| 2603514 | 122019000026 | Germany | Start Trial | PRODUCT NAME: VABORBACTAM, UND/ODER EIN SALZ UND/ODER EIN HYDRAT DAVON; REGISTRATION NO/DATE: EU/1/18/1334 20181120 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
